Pascal Krotee Ph.D

Principal

McKearn, John P.

Managing Director

Sivan Weitzman

CFO

36 past transactions

Good Therapeutics

Series B in 2021
Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology.

Biolinq

Series B in 2021
Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers, allowing diabetic patients to monitor their blood glucose levels.

Scout Bio

Series B in 2021
Scout Bio is a biotechnology company that specializes in veterinary, animal health, and gene therapy. The company is driven by its mission is to harness the genetic revolution transforming human medicine to deliver the future of veterinary medicine. Scout Bio was founded in 2016 and headquartered in Pennsylvania, United States.

Sparrow Pharmaceuticals

Series A in 2021
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for disorders of corticosteroid excess. It was founded to spare patients the ravages of steroids. Leveraging underappreciated scientific insights into corticosteroid biology, the company is working to provide better treatment options for serious disorders of hypercortisolism and to revolutionize the treatment of autoimmune and inflammatory conditions. Its lead product, SPI-62, is an oral, small molecule, a novel treatment designed to target the source of active intracellular corticosteroids in key tissues. The company was founded in 2013 by David A. Katz and is based in Portland, Oregon, United States.

Arch Oncology

Series C in 2021
Formerly Known as Vasculox. Arch Oncology is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. The company's functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses.

Reneo Pharmaceuticals

Series B in 2020
Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases. It focuses on the development of treatments for genetic disorders associated with defects in energy metabolism resulting in myopathy that enable caregivers to improve the daily function and quality of life of patients suffering from these diseases by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness, and wasting. The company was founded in 2014 and is headquartered in San Diego, California.

Amplyx Pharmaceuticals

Series C in 2020
Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.

Good Therapeutics

Series A in 2020
Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology.

Scout Bio

Series B in 2019
Scout Bio is a biotechnology company that specializes in veterinary, animal health, and gene therapy. The company is driven by its mission is to harness the genetic revolution transforming human medicine to deliver the future of veterinary medicine. Scout Bio was founded in 2016 and headquartered in Pennsylvania, United States.

Arch Oncology

Series B in 2019
Formerly Known as Vasculox. Arch Oncology is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. The company's functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses.

Mirum Pharmaceuticals

Series A in 2018
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Allakos

Series B in 2017
Allakos develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells. Its antibodies target cell types implicated in allergic and inflammatory responses. Allakos was founded in 2012 and is headquartered in San Carlos, California.

Neuros Medical

Series A in 2017
Neuros Medical is a neuromodulation company, is focused on developing proprietary therapies for the unmet needs of patients worldwide. The Company's patented platform technology, Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine.

Genoa Pharmaceuticals

Series A in 2017
Genoa Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of idiopathic pulmonary fibrosis (IPF). It develops GP-101, an aerosol pirfenidone formulation for direct inhalation delivery to the lungs for the treatment of IPF. The company was founded in 2011 and is based in San Diego, California.

Adarza BioSystems

Series C in 2017
Adarza BioSystems is an early-stage medical diagnostics company developing a rapid and label-free biological assay platform for measuring clinical and point-of-care (POC) samples. In addition to performing sophisticated clinical tests within minutes, this technology potentially allowing hundreds of tests to be run simultaneously on a single chip. It was founded in 2008 and headquartered in St Louis, Missouri.

Securus Medical Group

Series C in 2016
Securus Medical Group engages in the development of clinical tools to improve the safety and efficacy of ablation therapy by providing real-time, non-contact, high-resolution tissue temperature monitoring, and mapping products. The company engages in developing real-time, noncontact, thermal mapping systems to determine intrabody tissue temperatures.

Amplyx Pharmaceuticals

Series B in 2015
Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.

Lyric Pharmaceuticals

Series A in 2015
Lyric is a clinical-stage company developing novel gastrointestinal therapeutics for unmet medical needs in the hospital setting. It was founded in 2013 and is headquartered in San Francisco, California.

Smart Wires

Series B in 2014
Smart Wires is an electrical and electronics company that specializes in grid optimization solutions that leverage its patented modular power flow control technology. The company provides solutions in the fields of transmission reliability, congestion management, and power flow control solutions. Smart Wires was founded in 2010 and headquartered in San Francisco, California.

Allakos

Series A in 2014
Allakos develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells. Its antibodies target cell types implicated in allergic and inflammatory responses. Allakos was founded in 2012 and is headquartered in San Carlos, California.

Tryton Medical

Venture Round in 2014
Tryton Medical, Inc. develops stent systems for the treatment of cardiovascular diseases in the United States, Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom. It offers the Tryton Side Branch Stent System, which offers a strategy for treating atherosclerotic lesions in the side branch at the site of a bifurcation. The company was founded in 2003 and is based in Durham, North Carolina.

Allakos

Series A in 2014
Allakos develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells. Its antibodies target cell types implicated in allergic and inflammatory responses. Allakos was founded in 2012 and is headquartered in San Carlos, California.

Otonomy

Series D in 2014
Otonomy is an expert in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery. This approach has already been widely adopted for the delivery of short-acting antibiotics to treat otitis media through a tympanostomy tube. In addition, otolaryngologists have demonstrated that the injection of steroids into the middle ear cavity can provide a therapeutic effect for patients with acute inner ear disorders such as Ménière’s disease and sudden sensorineural hearing loss. Expansion of this effort holds great promise for the treatment of chronic hearing loss, severe vertigo, and even tinnitus. The key to Otonomy's leading position in this nascent field is the development of a proprietary formulation platform that provides sustained drug exposure from a single administration. Broad application of this technology has already been established across a number of therapeutic classes, and from these, three product candidates have been advanced into development.

Securus Medical Group

Series B in 2013
Securus Medical Group engages in the development of clinical tools to improve the safety and efficacy of ablation therapy by providing real-time, non-contact, high-resolution tissue temperature monitoring, and mapping products. The company engages in developing real-time, noncontact, thermal mapping systems to determine intrabody tissue temperatures.

Lumena Pharmaceuticals

Series A in 2013
Lumena Pharmaceuticals is developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health. The company’s clinical-stage product candidates carry a reduced risk of systemic toxicities by selectively targeting a transporter in the intestine and are designed to be minimally absorbed in the body. Lumena’s lead candidate, LUM001, has been extensively evaluated in other indications across 12 clinical studies in more than 1,400 subjects. Because of the extensive preclinical and clinical data package for a compound at this stage in development, LUM001 is positioned to rapidly progress through the clinic in pediatric and adult patients with several types of cholestatic liver disease. While Lumena’s primary focus is to develop novel treatments for patients with rare liver diseases, the company’s therapeutic approach also has promising potential in the treatment of metabolic diseases affecting the liver, a significant and growing health problem in children and adults.

Tryton Medical

Venture Round in 2013
Tryton Medical, Inc. develops stent systems for the treatment of cardiovascular diseases in the United States, Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom. It offers the Tryton Side Branch Stent System, which offers a strategy for treating atherosclerotic lesions in the side branch at the site of a bifurcation. The company was founded in 2003 and is based in Durham, North Carolina.

Smart Wires

Series A in 2012
Smart Wires is an electrical and electronics company that specializes in grid optimization solutions that leverage its patented modular power flow control technology. The company provides solutions in the fields of transmission reliability, congestion management, and power flow control solutions. Smart Wires was founded in 2010 and headquartered in San Francisco, California.

ZS Pharma

Series C in 2012
ZS Pharma is a privately held specialty pharmaceutical company based in Coppell, Texas, and Menlo Park, CA. Its core focus is the research and development of highly selective ion-trap therapies to treat serious medical conditions. The company'ss therapeutic candidate, ZS-9, is a novel treatment for hyperkalemia, a life-threatening condition that affects patients with chronic kidney disease, hypertension, diabetes, and/or chronic heart failure. Hyperkalemia is characterized by abnormally high concentrations of potassium in the blood. ZS-9 is currently being tested in late-stage clinical trials.

Neuros Medical

Series A in 2011
Neuros Medical is a neuromodulation company, is focused on developing proprietary therapies for the unmet needs of patients worldwide. The Company's patented platform technology, Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine.

Securus Medical Group

Series A in 2011
Securus Medical Group engages in the development of clinical tools to improve the safety and efficacy of ablation therapy by providing real-time, non-contact, high-resolution tissue temperature monitoring, and mapping products. The company engages in developing real-time, noncontact, thermal mapping systems to determine intrabody tissue temperatures.

Otonomy

Series B in 2010
Otonomy is an expert in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery. This approach has already been widely adopted for the delivery of short-acting antibiotics to treat otitis media through a tympanostomy tube. In addition, otolaryngologists have demonstrated that the injection of steroids into the middle ear cavity can provide a therapeutic effect for patients with acute inner ear disorders such as Ménière’s disease and sudden sensorineural hearing loss. Expansion of this effort holds great promise for the treatment of chronic hearing loss, severe vertigo, and even tinnitus. The key to Otonomy's leading position in this nascent field is the development of a proprietary formulation platform that provides sustained drug exposure from a single administration. Broad application of this technology has already been established across a number of therapeutic classes, and from these, three product candidates have been advanced into development.

MacroGenics

Series D in 2008
MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases. The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company's Fc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology. The company was founded in 2000 and is headquartered in Rockville, Maryland.

Xoft

Series D in 2007
Xoft, Inc. develops electronic brachytherapy (eBx) systems for radiation oncology applications. It offers Axxent Controller that utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed. The company also provides Axxent balloon applicator, a treatment solution for accelerated partial breast irradiation; Axxent vaginal applicator that enables radiation oncologists to perform vaginal brachytherapy; and Axxent surface applicator that enables radiation oncologists to treat surface lesions. In addition, it offers accessories, such as physics accessory kits, personnel protective shields, procedure accessory packs, patient care kits, applicator clamp and base plates, and vacuum pumps, as well as FlexiShield, which drapes over the patient treatment area to reduce radiation transmission to nearby healthy tissue and organs. The company's products are used to treat early stage breast cancer, skin cancer, and endometrial cancer. It offers its products through physicians and distributors in Europe. Xoft, Inc. was formerly known as Xoft microTube, Inc. and changed its name in September 2004. The company was founded in 1998 and is based in Sunnyvale, California.

Centerre Healthcare

Venture Round in 2005
Centerre Healthcare Corporation develops and operates rehabilitation hospitals. It offers programs for strokes, brain injuries, spinal cord injuries, burns, traumatic injuries, and hip/knee/orthopedic problems. The company also provides specialized rehabilitation services for medical, psychological, social, and functional needs of patients and families. Centerre Healthcare Corporation was founded in 2002 and is based in Brentwood, Tennessee.

Conforma Therapeutics

Series C in 2003
Conforma Therapeutics Corporation designs and develops drugs for the treatment of cancer. It develops drugs that induce tumor cells to degrade the proteins that promote cancer growth. The company offers HSP90 and CNF1010 which are used for the treatment of cancer. The company was incorporated in 1999 and is based in San Diego, California
Established in 1999, Salient Surgical Technologies, Inc. is a global, privately held medical technology company that develops and markets advanced energy devices used in surgical procedures. Salient’s first line of products were monopolar electrosurgical devices used for the treatment of liver cancers. Today, the company’s bipolar AQUAMANTYS® System is used across a wide range of surgical procedures including orthopaedic reconstruction, spine surgery, orthopaedic trauma, and surgical oncology. Comprised of a bipolar electrosurgical generator & pump system and a portfolio of handheld disposable device, the AQUAMANTYS system uses patented TRANSCOLLATION® technology to haemostatically seal soft tissue and bone, enabling surgeons to reduce and prevent surgical blood loss. Salient’s products are sold throughout the United States, Europe, and Asia, providing clinical and economic benefits to hospitals, healthcare providers, and patients all over the world. To date, more than 500,000 patients have been treated with TRANSCOLLATION technology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.